Marco's Morning Report — Thursday, July 9, 2026

Section A — Top Stories

New this week · clinical

Medicare's GLP-1 "Bridge" is live — more of your admits will be on Wegovy or Zepbound

As of July 1, eligible Medicare Part D beneficiaries can get GLP-1s approved for weight loss — Wegovy and Zepbound — for a $50/month copay through the temporary Medicare GLP-1 Bridge, now extended through December 2027. CMS negotiated a ~$245 net price per fill; enrollment is expected in the low millions initially and climbing.

Why it matters to you: This is the first time Medicare has paid for obesity GLP-1s, so the share of your elderly admits on semaglutide/tirzepatide is about to rise. Two bedside implications: (1) delayed gastric emptying — the 2024 multi-society/ASA guidance says most patients can continue GLP-1s before a procedure, but high-GI-risk patients need a 24-hr liquid diet and gastric POCUS is a reasonable check before sedation or intubation; (2) acute illness + GLP-1 = anorexia, nausea, dehydration, and AKI risk in a frail inpatient who's already not eating.

Action: Add "on a GLP-1?" to your admission med-rec habit for anyone with obesity or T2DM, and flag it explicitly for anesthesia/proceduralists rather than assuming it's held. AGA perioperative summary.

Update · world

Cuba back on the grid after its third nationwide blackout — but the fuel math hasn't changed

Update to the story we've tracked all week: Cuba fully reconnected its grid early Wednesday after Monday's total collapse left all ~9.6 million residents dark. Officials warn more outages are likely — the island produces only ~40% of the fuel it needs and the U.S. fuel blockade continues. President Díaz-Canel blamed U.S. sanctions; at the UN debate, most speakers called on Washington to lift the blockade while the U.S. envoy put the blame on Havana.

Why it matters to you: Family ties aside — Cuba has canceled tens of thousands of surgeries and its hospitals are running on generators. It's a real-time case study in what a health system looks like when the power and the pharmacy both run dry.

Section B — The Debate

Should Medicare be paying for weight-loss drugs?

Why it's live right now: The GLP-1 Bridge just switched on July 1, putting Wegovy and Zepbound in Part D beneficiaries' hands for $50 — and reopening a fight Washington has dodged for years about whether taxpayers should foot the bill for obesity drugs that could apply to tens of millions of seniors.

THE CASE FOR

Obesity is a chronic disease, and treating it like one is overdue: that's the argument behind the bipartisan Treat and Reduce Obesity Act, championed by Sen. Bill Cassidy (R-La.), himself a physician. Supporters — obesity-medicine clinicians and patient advocates who've pushed for coverage for years — point to the downstream cardiovascular, diabetes, and mobility benefits, and note the Bridge's negotiated ~$245 price is a fraction of the old $1,000+ sticker. Denying seniors a proven therapy that commercial and Medicaid plans increasingly cover, they argue, is an equity problem, not a fiscal virtue.

THE CASE AGAINST

The math is brutal. The Congressional Budget Office pegged full Medicare obesity-drug coverage at roughly $35 billion in net new federal spending over a decade, with only modest offsetting health savings; independent analyses land even higher. Critics — fiscal conservatives and some health economists — warn the "temporary" Bridge is a foot in the door for a permanent entitlement Medicare can't afford, and KFF's Juliette Cubanski flags the flip side for patients: when the 18-month program ends, enrollees could fall off a coverage cliff with no plan for what comes next.

Where it might land: The Bridge runs through Dec 31, 2027 — the real decision is whether Congress makes coverage permanent (via TROA or a successor) before then, or lets it lapse.

Section C — On My Radar

Mets split a tense series with Atlanta. Juan Soto's three-run, go-ahead homer in the 9th and a Torrens walk-off rescued a wild set against the Braves. Recap.

Mets bullpen bruises: RHP Austin Warren to the 15-day IL (MRI after prior Tommy John — worth watching). On the mend: Luis Robert Jr. (lumbar disc) and Jorge Polanco (Achilles bursitis) both back on rehab assignments at Triple-A Syracuse, targeting a mid-July return. Injury tracker.

Puerto Rico oversight board shake-up: reports that the Trump administration has removed six of seven members of PROMESA's Financial Oversight and Management Board — a move that could reshape (or reset) the island's fiscal oversight depending on the replacements. Context.

Movie for the queue: Wardriver, a lean cyber-heist thriller with Dane DeHaan, is sitting at a rare 100% on Rotten Tomatoes and is now streaming on Paramount+. Details.

Golf tech: no genuinely new hardware drop in the last 48h — the 2026 field (Full Swing Kit, Bushnell Launch Pro Circle B, Garmin Approach G82, Rapsodo MLM2Pro) is unchanged since the winter releases.

Section D — Trends to Watch

AI is now the default in hospital medicine — but training isn't keeping up. SHM's 2026 Workforce Experience report finds 64% of hospitalists using AI and 73% of those seeing benefit, yet only about a third feel adequately trained. Expect governance and documentation-liability questions to follow the tools onto the floor. SHM: five things to watch.

GLP-1 prescribing is about to become a geriatrics question, not just an endocrine one. With Medicare paying, watch for muscle-mass/sarcopenia and falls signals in older, frailer users — a population underrepresented in the original trials.

Section E — Ideas & Opportunities

Bring the GLP-1 question to your group. A one-line addition to the admission med-rec template ("GLP-1 agonist — last dose? held for procedure?") could pre-empt a lot of aspiration-risk and AKI headaches as the Bridge ramps up.

Queue Wardriver for a post-shift wind-down — 90 tight minutes, no franchise homework required.

Watch Soto's July. If he stays this hot into the deadline, the Mets' buy/sell calculus (and the bullpen shopping list after the Warren injury) gets a lot more interesting.

Section H — Background / Already Covered

Older items & ongoing context (tap to expand)

Cuba energy crisis (ongoing since spring): fuel blockade, ~20+ hr/day regional outages, suspended surgeries — the July 8 grid restoration above is the newest wrinkle, but the underlying collapse has been running for months.
AQUATIC trial (ESC 2025 / NEJM): in stabilized CAD patients >6 months post-PCI who need long-term anticoagulation, adding aspirin raised death, CV events, and major bleeding — trial stopped early. Not new, but a clean med-rec rule for your OAC patients: drop the aspirin. NEJM.
Florida property-insurance changes (effective July 1): claim-filing window cut to one year, insurers must decide within 60 days, and denials driven by AI now need documented human review. Relevant if you're a Florida homeowner more than a clinician.